Final answer:
For the administration of intravenous topotecan in a client with ovarian cancer, an implanted port or a 3. central line is the expected venous access site, due to the necessity for stable, long-term venous access in chemotherapy treatments.
Step-by-step explanation:
The student's question addresses the delivery of intravenous chemotherapeutic agents to a patient with ovarian cancer.
When considering which venous access site is appropriate for the administration of a chemotherapy drug like topotecan, an implanted port or a 3. central line is typically expected given the nature of the drug and the treatment regimen.
Peripheral venous access is generally used for short-term treatments, but chemotherapy often requires stable, long-term access that can tolerate the caustic nature of the drugs.
An implanted port or a central line provides such access and helps reduce the risk of complications associated with frequent needle sticks and peripheral vein damage.